` IMMVF (Immunovia AB (publ)) vs S&P 500 Comparison - Alpha Spread

IMMVF
vs
S&P 500

Over the past 12 months, IMMVF has underperformed S&P 500, delivering a return of -51% compared to the S&P 500's 10% growth.

Stocks Performance
IMMVF vs S&P 500

Loading
IMMVF
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
IMMVF vs S&P 500

Loading
IMMVF
S&P 500
Difference
www.alphaspread.com

Performance By Year
IMMVF vs S&P 500

Loading
IMMVF
S&P 500
Add Stock

Competitors Performance
Immunovia AB (publ) vs Peers

Immunovia AB (publ)
Glance View

Market Cap
3.3m USD
Industry
Health Care

Immunovia AB engages in the development of methods for diagnosing complex forms of cancer and autoimmune diseases. The company is headquartered in Lund, Skane and currently employs 65 full-time employees. The company went IPO on 2015-12-01. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.

IMMVF Intrinsic Value
0.0869 USD
Undervaluation 15%
Intrinsic Value
Price
Back to Top